Vedantra is an Immunotherapy Company focused on the treatment and cure of various types of cancer and infectious disease. Vedantra's technology was first developed in Professor Darrell Irvine's laboratory at MIT's Koch Institute.
Our current product candidates are in the area of HPV-induced cancers (including cervical cancer, and head and neck cancer), and other cancers expressing tumor-associated antigen targets. The proprietary Vedantra immunotherapy platform elicits highly potent tumor-specific, functional CD8 T cell responses with the potential to achieve tumor regression and cure in the clinic. We have further demonstrated a strong synergy in combination with immune modulating therapies, including various checkpoint inhibitors.
In the area of infectious disease, the Vedantra technology platform has been shown to elicit highly potent and durable antibody responses to target and prevent infection.